May 16 (Reuters) - The U.S. Food and Drug Administration granted accelerated approval to tarlatamab, Amgen's targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despite chemotherapy, Bloomberg News reported on Thursday. (Reporting By Deena Beasley; Editing by Bill Berkrot)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
300.7 USD | -1.32% | -2.17% | +4.40% |
06-10 | Transcript : Amgen Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM | |
06-07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.40% | 161B | |
+48.53% | 780B | |
+41.66% | 627B | |
-6.37% | 353B | |
+20.93% | 334B | |
+8.21% | 296B | |
+17.78% | 244B | |
-1.02% | 217B | |
+11.49% | 214B | |
-2.64% | 159B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- US FDA approves Amgen drug for small cell lung cancer, Bloomberg News reports